Extensive-stage Small Cell Lung Cancer
Conditions
Interventions
In the dose optimization part of the study (Part 1), participant will be randomized to receive Ifinatamab Deruxtecan (I-DXd) at 8 mg/kg or 12 mg/kg. In the extension part of the study (Part 2), partic
Sponsors
Inoguchi Akihiro
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Sign and date the informed consent form (ICF) prior to the start of any study-specific qualification procedures. 2. Participant must have at least one lesion, not previously irradiated, amenable to core biopsy. 3. Male or female subjects aged >=18 years 4. Histologically or cytologically documented ES-SCLC. 5. At least one measurable lesion according to RECIST v1.1 as assessed by the investigator. 6. Prior therapy with at least one platinum-based line as systemic therapy for extensive-stage disease with at least two cycles of therapy (except in the case of early objective PD) and beginning with protocol version 3.0, a minimum of two previous lines of systemic therapy. 7. Documentation of radiological disease progression on or after most recent systemic therapy. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Exclusion criteria
Exclusion criteria: 1. Prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd. 2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities. 3. Clinically active brain metastases, spinal cord compression or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. 4. Any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event. 5. Clinically significant corneal disease. 6. Uncontrolled or significant cardiovascular disease. 7. History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 8. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses. 9. Chronic steroid treatment (maximum dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD) or topical steroids (for mild skin conditions) or intra-articular steroid injections. 10. History of malignancy other than SCLC within the 3 years prior to enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal (GI) tract tumors and non-muscle invasive bladder cancer curatively resected by endoscopic surgery. 11. History of allogeneic bone marrow, stem cell, or solid organ transplant. 12. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0), Grade <=1 or baseline. 13. History of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies. 14. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. 15. Has active or uncontrolled hepatitis B or C infection. 16. Active, known, or suspected autoimmune disease. 17. Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, psychiatric illness/social situations, substance abuse). 18. Has received a live vaccine within 30 days prior to the first dose of study drug. 19. Female who is pregnant or breast-feeding or intends to become pregnant during the study. 20. Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant. 21. Known human immunodeficiency virus (HIV) infection that is not well controlled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: Up to approximately 36 months ] ORR was the defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: Up to approximately 36 months ] TEAEs are defined as new adverse events (AEs) that occur after the dose of study drug or as AEs that were present prior to the dose of study drug but which worsened in severity after the start of study drug. 2. Progression-Free Survival (PFS) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: From enrollment until disease progression or death (whichever occurs first), up to approximately 36 months ] PFS is defined as the time interval from the date of enrollment to the date of disease progression based on RECIST v1.1 criteria or death due to any cause. PFS will be assessed by BICR and investigator. 3. Duration of Response (DoR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: From enrollment until disease progression or death (whichever occurs first), up to approximately 36 months ] DoR is defined as the time from the date of first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression based on RECIST v1.1 criteria or to death due to any cause, whichever occurs first. DoR will be assessed by BICR and investigator. 4. Overall Survival (OS) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: From enrollment until death, up to approximately 36 months ] OS is defined as the time interval from the date of enrollment to the date of death due to any cause or last contact follow-up, whichever occurs first. 5. Time to Response (TTR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC [ Time Frame: From enrollment until disease progression or death (whichever occurs first), up to approximately 36 months ] TTR is defined as the time from the date of enrollment to the first documentation of objective tumor respon | — |
Countries
China, France, Germany, Japan, Korea, Spain, Taiwan, United States
Contacts
Public ContactContact for Clinical Trial Information
DAIICHI SANKYO Co.,Ltd.
Outcome results
None listed